Addex Therapeutics’ Post

View organization page for Addex Therapeutics, graphic

6,536 followers

May is stroke awareness month. When stroke occurs, its vital to act F.A.S.T. to minimize lasting damage such as motor paralysis, loss of sensory function, impaired autonomic functions and impaired cognition leading to deficits in communication, attention and memory. There are currently no drugs to support sensorimotor recovery from stroke and current therapies rely on retraining and physiotherapy, with rehabilitation. At Addex Therapeutics, we are testing dipraglurant, a metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) as a potential treatment for post-stroke sensorimotor recovery. Our aim is to begin phase 2 clinical studies in 2024. #strokemonth

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics